Management of relapsing-remitting multiple sclerosis: Defining the role of subcutaneous recombinant interferon-β-1a (Rebif®)

Disease Management and Health Outcomes

Volumn 10, Issue 5, 2002, Pages 307-325

  Lyseng Williamson, Katherine A ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Disease management; Interferon 1a; Multiple sclerosis; Review on treatment

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; MITOXANTRONE;

ARTICLE; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INFLAMMATION; INJECTION SITE; LIVER DISEASE; LONG TERM CARE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; RELAPSE; REMISSION; TREATMENT PLANNING;

EID: 0036091288     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200210050-00004     Document Type: Article

References (136)

1. How many people in the world have multiple sclerosis?
2. Recombinant interferon-β-1a: A review of its therapeutic efficacy in relapsing-remitting multiple sclerosis
3. The epidemiology of multiple sclerosis
4. Epidemiology of multiple sclerosis: A critical overview
5. Revised estimate of the prevalence of multiple sclerosis in the United States
6. Epidemiology and estimated population burden of selected autoimmune diseases in the United States
7. An epidemiologic study of multiple sclerosis in Northern Ireland
8. An epidemiological study of multiple sclerosis in central Sardinia, Italy
9. The prevalence of multiple sclerosis in the Leeds Health Authority
10. Multiple sclerosis in Mostoles, central Spain
11. Prevalence of multiple sclerosis in Rochdale
12. Multiple sclerosis in Giljon health district, Asturias, northern Spain
13. Multiple sclerosis in Fife
14. Multiple sclerosis in Spain: An epidemiological study of the Alcoy health region, Valencia
15. The prevalence of multiple sclerosis in the Southampton and South West Hampshire Health Authority
16. Multiple sclerosis in Australia and New Zealand: Are the determinants genetic or environmental?
17. The natural history of multiple sclerosis: A geographically based study: I. Clinical course and disability
18. Prevalence of multiple sclerosis in Saskatoon
19. Prevalence of multiple sclerosis in British Columbia
20. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota
21. Latitude, migration, and the prevalence of multiple sclerosis
22. Multiple sclerosis
23. Epidemiology of multiple sclerosis in Arabs in Jordan: A comparative study between Jordanians and Palestinians
24. High incidence and prevalence of multiple sclerosis in south east Scotland: Evidence of a genetic predisposition
25. Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis
26. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis
27. Evidence for genetic basis of multiple sclerosis
28. British Isles survey of multiple sclerosis in twins
29. Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies
30. On the possible viral aetiology of multiple sclerosis
31. Viruses and multiple sclerosis
32. Epstein-Barr virus antibodies and risk of multiple sclerosis: A propective study
33. Defining the course of multiple sclerosis: Results of an international survey
34. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
35. Biotechnological agents for the immunotherapy of multiple sclerosis: Principles, problems and perspectives
36. Glatiramer acetate or interferon-β for multiple sclerosis? A guide to drug choice
37. Multiple sclerosis: What have we learned from magnetic resonance imaging studies?
38. Remyelination in multiple sclerosis: A challenge for therapy. The 1996 European Charcot Foundation Lecture
39. Neurodegeneration in multiple sclerosis: Relationship to neurological disability
40. Axonal damage in multiple sclerosis lesions
41. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss
42. Axonal transection in the lesions of multiple sclerosis
43. Prognostic value of brain MRI in clinically isolated syndromes of the CNS: A 10-year follow-up
44. Longitudinal study of abnormalities on MRI and disability from multiple sclerosis
45. The natural history of multiple sclerosis
46. Use of interferon beta in multiple sclerosis; rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response
47. Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis
48. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study
49. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
50. Treat early, but treat hard: Interferon-β dose makes a difference
51. Choosing drug therapy for multiple sclerosis: An update
52. The economics of multiple sclerosis: Distribution of costs and relationship to disease severity
53. A comprehensive assessement of the cost of multiple sclerosis in the United States
54. The economic cost of multiple sclerosis in Sweden in 1994
55. Health care costs of veterans with multiple sclerosis: Implications for the rehabilitation of MS
56. The cost of multiple sclerosis
57. The economics of multiple sclerosis: A cost of illness study
58. Economic consequences of multiple sclerosis for Canadians
59. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns and prediction
60. Economic evaluation of multiple sclerosis in the UK, Germany and France
61. The management of multiple sclerosis: Current and future therapies
62. Outcomes assessment of drug treatment in multiple sclerosis clinical trials
63. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
64. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS
65. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
66. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo- controlled trial
67. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
68. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
69. A review of the clinical efficacy profile of copolymer 1: New US phase III trial data
70. International consensus statement on the use of disease-modifying agents in multiple sclerosis
71. Task force on minimum standards for health care of people with multiple sclerosis: June 1999
72. Multiple sclerosis: A pharmacotherapy update
73. Management of impairment, disability, and handicap due to multiple sclerosis
74. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
75. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
76. Assessing efficacy in clinical trials of treatments for multiple sclerosis: Issues and controversy
77. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta-1a in relapsing-remitting multiple sclerosis
78. Pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain
79. Prescribing recommendations for interferon-beta in multiple sclerosis
80. Interferon beta in the treatment of multiple sclerosis: Mechanisms of action
81. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis
82. Interferon beta-1b is effective in relapsing/remitting multiple sclerosis. II. MRI analysis result of a multicenter randomized, double-blind, placebo-controlled trial
83. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis
84. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis
85. Interferon β-1a and depression in relapsing-remitting multiple sclerosis: An analysis of depression data from the PRISMS clinical trial
86. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
87. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
88. Immunogenicity of interferon-βin multiple sclerosis patients: Influence of preparation, dosage, dose frequency and route of administration
89. Neutralizing antibodies to interferon-β in the treatment of multiple sclerosis: Cause for concern?
90. Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are cross-reactive
91. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b
92. Copaxone (glatiramer acetate for injection)
93. Mechanisms of action of glatiramer acetate in multiple sclerosis
94. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
95. The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis: A multi-center randomized, double-blind placebo-controlled study extended by open-label treatment
96. Safety profile of copolymer 1: Analysis of cumulative experience in the United States and Israel
97. Antibodies to copolymer 1 do not interfere with its clinical effect
98. The effect of interferon-beta on blood brain barrier disruption demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis
99. Structural analysis of human interferon beta (IFNβ): Studies addressing the activity differences between IFNβ-1a and IFNβ-1b
100. Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers
101. Therapeutic strategies for multiple sclerosis: Success, failure - What next?
102. Rational clinical immunotherapy for multiple sclerosis
103. Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis
104. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-Month clinical and MRI outcome
105. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
106. Intravenous immunoglobulin treatment in multiple sclerosis: Effect on relapses
107. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis
108. Overview of azathioprine treatment in multiple sclerosis
109. New treatments and azathioprine in multiple sclerosis
110. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis
111. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis
112. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers
113. Pharmacokinetics (PK) and pharmacodynamics (PD) of interferon β-1a in healthy volunteers
114. The evidence study: Direct comparative study of IFN beta-1A three times weekly (Rebif) and once weekly (Avonex) in RRMS
115. A comparative study of the relative bioavailability of different interferon beta preparations
116. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration
117. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFNβ-1a) products administered intramuscularly in healthy male and female volunteers
118. Evidence of interferon β-1a dose response in relapsing-remitting MS: The OWIMS study
119. Interferon beta-1a in relapsing-remitting multiple sclerosis
120. Interferon-beta in the treatment of multiple sclerosis: Do clinical data support the existence of a ceiling effect?
121. Interferon beta treatment for multiple sclerosis; evidence for a clinically relevant dose response
122. Results of the European interferon beta-1a (Avonex) dose-comparison study
123. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-β
124. Influence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers
125. Pharmacodynamic responses to r-hIFN β 1a administered subcutaneously once-a-week (QW) or three-times-a-week (TIW), over one month
126. Recombinant human interferon-β-1a (Rebif) vs recombinant interferon-β-1b (Betaseron) in healthy volunteers: A pharmacodynamic and tolerability study
127. A cost-utility analysis of interferon beta for multiple sclerosis
128. The cost of delaying treatment in multiple sclerosis: What is lost is not regained